HR-POSITIVE/HER2-NEGATIVE METASTATIC BREAST CANCER
Clinical trials for HR-POSITIVE/HER2-NEGATIVE METASTATIC BREAST CANCER explained in plain language.
Never miss a new study
Get alerted when new HR-POSITIVE/HER2-NEGATIVE METASTATIC BREAST CANCER trials appear
Sign up with your email to follow new studies for HR-POSITIVE/HER2-NEGATIVE METASTATIC BREAST CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Which drug first? new study aims to improve breast cancer treatment order
Disease control Not yet recruitingThis study looks at two powerful drugs, sacituzumab govitecan (SG) and trastuzumab deruxtecan (T-DXd), for people with a certain type of advanced breast cancer (HER2-low/TROP2-high). The goal is to find out which drug works best when given first and how to switch if the first sto…
Matched conditions: HR-POSITIVE/HER2-NEGATIVE METASTATIC BREAST CANCER
Phase: PHASE2 • Sponsor: Fudan University • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New combo therapy aims to slow advanced breast cancer in patients who relapsed
Disease control Not yet recruitingThis study tests whether a combination of two drugs (fulvestrant and ribociclib) works better than standard treatments for people with a certain type of advanced breast cancer (HR+, HER2-). The cancer has returned after the patient finished a prior course of CDK4/6 inhibitors. Ab…
Matched conditions: HR-POSITIVE/HER2-NEGATIVE METASTATIC BREAST CANCER
Phase: PHASE2 • Sponsor: Yeon Hee Park • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC
-
New hope for advanced breast cancer: drug combo trial launches
Disease control Not yet recruitingThis early-stage trial tests a drug called sacituzumab govitecan combined with hormone therapy in 12 people with HR-positive, HER2-negative metastatic breast cancer that has worsened after CDK4/6 inhibitor treatment. The main goal is to check safety and side effects, while also l…
Matched conditions: HR-POSITIVE/HER2-NEGATIVE METASTATIC BREAST CANCER
Phase: PHASE1 • Sponsor: Hunan Cancer Hospital • Aim: Disease control
Last updated Jun 26, 2026 17:41 UTC